Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Analyst Rating Guide

News

Back

AnaptysBio Q4 EPS $(1.59) Beats $(1.60) Estimate, Sales $9.01M Beat $2.23M Estimate

Author: Happy Mohamed | March 11, 2024 04:29pm

AnaptysBio (NASDAQ:ANAB) reported quarterly losses of $(1.59) per share which beat the analyst consensus estimate of $(1.60) by 0.63 percent. This is a 70.97 percent decrease over losses of $(0.93) per share from the same period last year. The company reported quarterly sales of $9.01 million which beat the analyst consensus estimate of $2.23 million by 303.81 percent. This is a 32.27 percent increase over sales of $6.81 million the same period last year.

Posted In: ANAB